GCC-2004

N/A

Report date: 2024/11/27 15:02:51

Base Information

Drug NameGCC-2004

Drug Alias NameGCC2004GCC-2004

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsNatural killer cell replacements

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLeukemia, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesGC Cell Corp

China Registration ClassN/A

Develop Information

Active CompaniesGC Cell Corp

Inactive CompaniesN/A

Active IndicationsLeukemia, B-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A